Last reviewed · How we verify

NCT03160053

Improving Keloids Using Targeted Ultraviolet-B Irradiation

Completed NA Last updated 19 June 2018
What this trial tests

NA trial testing NB-UVB in Keloid in 2 participants. Completed in 15 June 2018.

Timeline
23 June 2015
Primary endpoint
20 November 2015
15 June 2018

Quick facts

Lead sponsorJohns Hopkins University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment2
Start date23 June 2015
Primary completion20 November 2015
Estimated completion15 June 2018

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

18 and older, any sex, with Keloid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Current State of Clinical Trials for Keloid Management: An Analysis of Trials Registered on ClinicalTrials.gov.
    Park S, Li D, Guo L, Xu X. · · 2026 · PMID 42077711 · DOI 10.7759/cureus.106243

Verify or expand the search:

Other trials of NB-UVB

Trials testing the same drug.

Other recruiting trials for Keloid

Currently open trials in the same condition.

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03160053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing